Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA.
Journal: The Journal of infectious diseases
Published: February 11, 2026
Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen.
Journal: Open forum infectious diseases
Published: April 24, 2025
Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial.
Journal: AIDS (London, England)
Published: April 10, 2025
Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical Trials.
Journal: Open forum infectious diseases
Published: December 10, 2024
Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes.
Journal: AIDS (London, England)
Published: December 11, 2023
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: October 08, 2020
Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate.
Journal: Antimicrobial agents and chemotherapy
Published: September 25, 2019
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: April 16, 2019
Evaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: March 26, 2019
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: May 18, 2018
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
Journal: The lancet. Gastroenterology & hepatology
Published: March 27, 2017
Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: February 02, 2017
Last Updated: 09/26/2026